Royalty Pharma officer proposes $1.66M share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Royalty Pharma plc (RPRX) officer Christopher Hite reported a proposed sale of 30,000 Class A ordinary shares, with an aggregate market value of $1,660,500 and an approximate sale date of June 23, 2026. The shares were acquired from the issuer on June 18, 2020, through its IPO - Reserved Shares Program. The proposed sale is connected to a selling plan dated March 20, 2026, intended to comply with Rule 10b5-1(c).
Key Figures
Key Terms
Rule 10b5-1(c) regulatory
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What plan is connected to Christopher Hite's proposed RPRX sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.